Nexus Research

Disclaimer: Please note the below information is for our patients and service users who are interested in the research we are currently participating in. This is not a recruitment page. If appropriate, your GP will invite you to participate in a research study on a case by case basis. It is not possible to request access to a study.

Clinical research network: South London

Dementia Research is a service which allows people to register their interest in national dementia research.

It helps people with dementia, their carers, or anyone interested in dementia research to be matched to studies. Once registered, your details will be stored securely, and will be regularly checked to see if you match to studies. Find out more here: www.joindementiaresearch.nihr.ac.uk

Bioresouce

Recruit for studies on common diseases, rare diseases and even healthy populations. Due to the specialist work needed to support COVID research we have a special section for that too. We can recall members who wish to take part in further studies. 
Find out more here: www.bioresource.nihr.ac.uk


Developing and delivering targeted SARS-CoV-2 (COVID-19) health interventions to Black, Asian and Minority Ethnic (BAME) communities living in the UK. The COBHAM Study.

To reduce health inequalities and COVID-19 risk by delivering targeted, culturally appropriate health interventions to Black and South Asian communities.


ComCOV3 study

The purpose of this study is to test how well young people (aged 12-16 years) respond to two doses of COVID-19 vaccine, comparing three different vaccines.


*RAPID™ [Restorative Autologous Platelet biotherapies for Injuries & Delayed wound healing] Biodynamic Haematogel.

The primary objective of this pilot study, is to determine safety and efficacy of additional RAPID™ Biodynamic Haematogel (RAPID™ Gel) treatment to usual and customary care, in complete wound healing of chronic diabetic foot ulcers, within 12 weeks.


A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents with Autism Spectrum Disorders. (STAR AIMs)

The objective of the study is to explore the efficacy, safety and tolerability of arbaclofen administered to children and adolescents (ages 5-17) for the treatment of impairments in social adaptive behaviours in participants with Autism Spectrum Disorders (ASD).

The effects of arbaclofen on social function in children and adolescents with ASD will be evaluated in a randomized, placebo-controlled, parallel-group study of 16 weeks duration.


Sativex® for the Treatment of AgitatioN in
Dementia (‘STAND’) trial

The STAND trial aims to explore the feasibility of a licensed cannabinoid oral spray (Sativex®) for the treatment of behavioural and psychological symptoms, such as agitation and anxiety, in people living with Alzheimer’s disease in nursing homes. Please click here for more info.


The PROFILE Study: Germline genetic profiling: correlation with targeted prostate cancer screening and treatment.

A type of research study to compare interventions in clinical practice. This study to investigate the role of targeted prostate cancer screening in men at a higher genetic risk (i.e. family history, ethnicity) and its association with specific genetic profiles and biomarkers.

Prostate cancer (PrCa) is now the commonest cancer in men in the Western world. The PROFILE study aims to determine the association of genetic profile with prostate biopsy result in men at genetically higher prostate cancer risk undergoing targeted prostate cancer screening.

Investigations will be:

- PSA screening; blood for genetic profiling and other tests; urine samples for biomarker analyses; MRI and prostate biopsy


MultiCath

A non-inferiority, two-arm, participant randomized, controlled trial comparing mixed catheter use (single use catheters and re-usable catheters) with single catheter use only in adults doing intermittent self-catheterization.


Aspirin To Target Arterial events in Chronic Kidney Disease (ATTACK)

This study aims to find out whether people with chronic kidney disease (CKD) should take daily low-dose aspirin to reduce the risk of a first heart attack or stroke (cardiovascular disease, CVD).

We want to determine whether aspirin should be given to people with CKD to prevent a first heart attack or stroke (primary prevention). As CVD is more common in people with CKD than in the general population we would expect aspirin to be of greater benefit, but the risks of bleeding may also be higher. Before we can recommend aspirin for primary prevention in people with CKD we need to be sure that the benefits outweigh the possible risks.


A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression : LQD

Longitudinal study comparing two treatment options in Treatment Resistant Depression (TRD) using weekly depression symptom monitoring.


A novel online program for fatigue; a feasibility study (FLEX)

This is an intervention study for people with fatigue- specifically people with chronic fatigue syndrome, multiple sclerosis or are in remission from breast or prostate cancer.

The aim is to see whether a short online program can help people with fatigue manage the impact of their symptoms in daily life.

Research has shown that Long Term Conditions (LTC’s) are associated with high levels of fatigue, depression, anxiety, distress and disability. Unhelpful or negative thinking styles may play a role in the perpetuation and maintenance of symptoms of fatigue and distress. This study aims to develop more positive, adaptive thinking styles using an online training program.


PRINCIPLE-Platform Randomised trial of Interventions against COVID-19 In older people

COVID-19 disproportionately affects people over 50 years old with comorbidities and those over 65 years old. The infection causes considerable morbidity and mortality in this population group in particular, and is having a devastating effect on people's health and society internationally. So far, there are no treatments for COVID-19 that have been proven in rigorous clinical trials to be effective. It is essential to identify interventions that may favourably modify progression of the infection.


ATP - Antidepressant Trial with P2X7 Antagonist JNJ-54175446

Major depression disorder (MDD) is one of the most important causes of disability. Although treatments are available, about a third of patients are treatment-resistant. There is growing interest in the role of the immune system in depression. It’s suggested anti-inflammatory mechanisms may offer an approach to treat depression. The purinergic receptor P2X7 plays a key role in release of inflammatory molecules during stress, which may be linked to stress related depression. This trial aims to find out if blocking the P2X7 receptor with antagonist JNJ-54175446, compared with placebo in people with treatment resistant MDD, who have genetic profiles that indicate high levels of P2X7 receptor signalling, can relieve symptoms of depression.


Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation (ASPIRE DNA)

The Aspire-DNA study is looking at the effectiveness of a DNA-based diet on reducing the risk of diabetes in people at high risk.